Education
About Us
Working with TipRanks
Follow Us
Rallybio (RLYB)
NASDAQ:RLYB
RLYB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $1.41
Previous CloseN/A
Volume36.64K
Average Volume (3M)5.65M
Market Cap
$19.57M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 06, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding41,613,964
10 Day Avg. Volume609,008
30 Day Avg. Volume5,653,621
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.00Price Target Upside117.39% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Financial StabilityRallybio ended with $66M in cash, which provides runway into the second half of 2026.
Market OpportunitiesRLYB212 is viewed as a potential transformative option for mothers at risk of FNAIT, and a blockbuster opportunity with epidemiological data suggesting more than 30,000 at-risk pregnancies annually in the U.S. and EU.
Pipeline DevelopmentPhase 1 data for differentiated C5 inhibitor RLYB116 could draw investor interest back to RLYB.
Bears Say
Clinical Trial ChallengesThe decision to discontinue RLYB212 was based on pharmacokinetic (PK) data from the Phase 2 trial indicating the inability to achieve predicted target concentrations, as well as the minimum target concentration required for efficacy.
Clinical Trial RisksRisks include delays in clinical trials and failure to generate favorable clinical data for key pipeline candidates.
Stock ValuationRLYB shares were already trading at a steep discount to its cash balance before the discontinuation of RLYB212.
Rallybio News
RLYB FAQ
What was Rallybio’s price range in the past 12 months?
Rallybio lowest stock price was $0.22 and its highest was $1.41 in the past 12 months.
What is Rallybio’s market cap?
Rallybio’s market cap is $19.57M.
When is Rallybio’s upcoming earnings report date?
Rallybio’s upcoming earnings report date is Aug 06, 2025 which is in 5 days.
How were Rallybio’s earnings last quarter?
Rallybio released its earnings results on May 08, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.26 by $0.05.
Is Rallybio overvalued?
According to Wall Street analysts Rallybio’s price is currently Undervalued.
Does Rallybio pay dividends?
Rallybio does not currently pay dividends.
What is Rallybio’s EPS estimate?
Rallybio’s EPS estimate is -0.25.
How many shares outstanding does Rallybio have?
Rallybio has 41,613,964 shares outstanding.
What happened to Rallybio’s price movement after its last earnings report?
Rallybio reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.26. Following the earnings report the stock price went down -3.333%.
Which hedge fund is a major shareholder of Rallybio?
Currently, no hedge funds are holding shares in RLYB
Rallybio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (117.39% Upside)
$1.00 (117.39% Upside)
Blogger Sentiment
Bearish
RLYB Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Negative
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.07%
12-Months-Change
Fundamentals
Return on Equity
-67.28%
Trailing 12-Months
Asset Growth
-41.64%
Trailing 12-Months
Company Description
Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
RLYB Stock 12 Month Forecast
Average Price Target
$1.00
▲(117.39%Upside)
Technical Analysis
Minerva Neurosciences
―
Moleculin Biotech
―
Marker Therapeutics
―
Addex Therapeutics
―
SeaStar Medical Holding
―
Ownership Overview
14.45%
Insiders
3.09% Mutual Funds
4.07% Other Institutional Investors
76.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---